Difference in pre-and postchemotherapy vascular endothelial growth factor levels as a prognostic indicator in osteosarcoma

Journal of International Medical Research

Volumn 39, Issue 4, 2011, Pages 1474-1482

  Qu, Y ^a   Xu, J ^a   Jiang, T ^a   Zhao, H ^a   Gao, Y ^a   Zheng, C ^a   Shi, X ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Osteosarcoma; Prognosis; Survival; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANTINEOPLASTIC AGENT; VASCULOTROPIN;

ADOLESCENT; ADULT; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; POST CANCER CHEMOTHERAPY; PRE CANCER CHEMOTHERAPY; PREDICTIVE VALUE; PRESCHOOL CHILD; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL TIME;

EID: 80052201032     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900436     Document Type: Article

References (30)

1. Homa DM, Sower M R, Schwartz AG: Incidence and survival rates of children and young adults with osteosarcoma. Cancer 1991; 67: 2219-2223.
2. Yonemoto T, Tatezaki S, Ishii T, et al: Prognosis of osteosarcoma with pulmonary metastases at initial presentation is not dismal. Clin Orthop Relat Res 1998, 349: 194-199.
3. Meyers PA, Gorlick R: Osteosarcoma. Pediatr Clin North Am 1997; 44: 973-989.
4. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790.
5. Bakhshi S, Radhakrishnan V: Prognostic markers in osteosarcoma. Expert Rev Anticancer Ther 2010; 10: 271-287.
6. Ferrari S, Bertoni F, Mercuri M, et al: Predictive factors of disease-free survival for nonmetastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 2001; 12: 1145-1150.
7. Folkman J: What's the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
8. Peng F, Chen M: Antiangiogenic therapy: a novel approach to overcome tumor hypoxia. Chin J Cancer 2010; 29: 715-720.
9. DuBois S, Demetri G: Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 2007; 109: 813-819.
10. Detwiller KY, Fernando NT, Segal NH, et al: Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res 2005; 65: 5881-5889.
11. Koshikawa N, Iyozumi A, Gassmann M, et al: Constitutive upregulation of hypoxia-inducible factor-1α mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure. Oncogene 2003, 22: 6717-6724.
12. Kaya M, Wada T, Kawaguchi S, et al: Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 2002; 86: 864-869.
13. Ek ETH, Ojaimi J, Kitagawa Y, et al: Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncol Rep 2006; 16: 17-23.
14. Huvos AG, Rosen G, Marcove RC: Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977; 101: 14-18.
15. Rosen G: Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics 1985; 8: 659-664.
16. Enneking WF: A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986; 204: 9-24.
17. Takenaka K, Ishikawa S, Yanagihara K, et al: Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer. Ann Surg Oncol 2005; 12: 817-824.
18. Kim MS, Song WS, Cho WH, et al: Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res 2007; 459: 229-236.
19. Bacci G, Ferrari S, Longhi A, et al: High-dose ifosfamide in combination with high-dose methotrexate, doxorubicin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother 2002; 14: 198-206.
20. Bispo Júnior RZ, Camargo OP: Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy. Clinics (Sao Paolo) 2009; 64: 1177-1186.
21. Broadhead ML, Akiyama T, Choong PF, et al: The pathophysiological role of PEDF in bone diseases. Curr Mol Med 2010; 10: 296-301.
22. Abdeen A, Chou AJ, Healey JH, et al: Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 2009; 115: 5243-5250.
23. Mohammed RA, Green A, El-Shikh S, et al: Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 2007; 96: 1092-1100.
24. Mei J, Gao Y, Zhang L, et al: VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro. Exp Oncol 2008; 30: 29-34.
25. Kyzas PA, Stefanou D, Batistatou A, et al: Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 2005; 131: 624-630.
26. Mantadakis E, Kim G, Reisch J, et al: Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma. J Pediatr Hematol Oncol 2001; 23: 286-289.
27. Huang Y, Lin Z, Zhuang J, et al: Prognostic significance of αV integrin and VEGF in osteosarcoma after chemotherapy. Onkologie 2008; 31: 535-540.
28. Kaya M, Wada T, Akatsuka T, et al: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000; 6: 572-577.
29. Hara H, Akisue T, Fujimoto T, et al: Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. Anticancer Res 2006; 26: 4307-4311.
30. Rossi B, Schinzari G, Maccauro G, et al: Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. BMC Musculoskelet Disord 2010; 11: 34.